Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Review of tipranavir in the treatment of drug-resistant HIV

Authors Hendrik Streeck, Jürgen Kurt Rockstroh

Published 15 September 2007 Volume 2007:3(4) Pages 641—651

Hendrik Streeck, Jürgen Kurt Rockstroh

Department of Medicine I, University of Bonn, Bonn, Germany

Abstract: Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of patients with HIV. Low adherence and toxicity among HIV-positive patients starting HAART, however, can lead to discontinuation of therapy and limit long-term treatment success. Moreover, increasing prevalence of primary resistance (>10%) as well as the accumulation of mutations resulting from continued selection pressure exerted by ongoing antiretroviral treatment in patients failing virologically, mean that new compounds are needed that retain antiretroviral activity against resistant strains. Tipranavir (Aptivus®) is a novel protease inhibitor (NPPI), which is characterized by a unique genetic resistance profile that allows it to remain active against HIV strains resistant to currently licensed protease inhibitors (PIs). Tipranavir was approved and licensed in the US and Europe in 2005 for treatment-experienced patients. This review summarizes the currently available data and studies on tipranavir and discusses the possible position of tipranavir in the currently available armamentarium of antiretroviral drugs.

Keywords: tipranavir, resistance, salvage, AIDS

Download Article [PDF] 

Readers of this article also read:

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

The impact of hearing loss on the quality of life of elderly adults

Ciorba A, Bianchini C, Pelucchi S, Pastore A

Clinical Interventions in Aging 2012, 7:159-163

Published Date: 15 June 2012

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Regular use of traditional analgesics predicts major coronary events: A cohort study

Mikko Haara, Markku Heliövaara, Jari PA Arokoski, Paul Knekt, Pirjo Manninen, et al

Therapeutics and Clinical Risk Management 2009, 5:9-15

Published Date: 2 December 2008

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Glen C MacDonald, Michèle Rasamoelisolo, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, et al

Drug Design, Development and Therapy 2008, 2:105-114

Published Date: 25 June 2008

A review of the use of adapalene for the treatment of acne vulgaris

Suleyman Piskin, Erol Uzunali

Therapeutics and Clinical Risk Management 2007, 3:621-624

Published Date: 15 September 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007